EQT agrees to acquire Qiagen in major diagnostics takeover
Swedish private equity firm EQT has agreed to acquire Dutch molecular testing company Qiagen for approximately €9.6 billion ($10.8 billion) in an all-cash voluntary public takeover offer at €46.50 per share, representing a 40.3% premium to the unaffected share price. The deal ends years of takeover speculation surrounding the diagnostics firm.
